CN102803225A - 咪唑衍生物和它们作为细胞周期蛋白依赖性激酶调节剂的应用 - Google Patents
咪唑衍生物和它们作为细胞周期蛋白依赖性激酶调节剂的应用 Download PDFInfo
- Publication number
- CN102803225A CN102803225A CN201080029384XA CN201080029384A CN102803225A CN 102803225 A CN102803225 A CN 102803225A CN 201080029384X A CN201080029384X A CN 201080029384XA CN 201080029384 A CN201080029384 A CN 201080029384A CN 102803225 A CN102803225 A CN 102803225A
- Authority
- CN
- China
- Prior art keywords
- randomly
- ketone
- alkyl
- substituting group
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(*)C(c1c*(C)*c(C)*1)=O Chemical compound C*(*)C(c1c*(C)*c(C)*1)=O 0.000 description 7
- PCFOHVMHSWBDFT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1Oc1ccc2nc[nH]c2n1)=O Chemical compound CC(C)(C)OC(N(CC1)CC1Oc1ccc2nc[nH]c2n1)=O PCFOHVMHSWBDFT-UHFFFAOYSA-N 0.000 description 1
- VFMXFWKMRJHRET-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)CCN1c1cc(nc(C(c2ccnc(-c3cncc4c3cccc4)c2)=O)[nH]2)c2nc1)=O Chemical compound CC(C)(C)OC(N(CCC1)CCN1c1cc(nc(C(c2ccnc(-c3cncc4c3cccc4)c2)=O)[nH]2)c2nc1)=O VFMXFWKMRJHRET-UHFFFAOYSA-N 0.000 description 1
- WEOITAJAXKFXCN-UHFFFAOYSA-N CC(C)(C)OC([n]1nc(C)c(-c2cc(C(c([nH]3)nc(cc4)c3nc4N(CC3)CCC3N(C)C)=O)ccn2)c1C)=O Chemical compound CC(C)(C)OC([n]1nc(C)c(-c2cc(C(c([nH]3)nc(cc4)c3nc4N(CC3)CCC3N(C)C)=O)ccn2)c1C)=O WEOITAJAXKFXCN-UHFFFAOYSA-N 0.000 description 1
- YTQVHCYNJSQYBQ-UHFFFAOYSA-N CC(C)(C1=O)NCCN1c1ccc2nc(C(c(cc3-c4c(C)[n](C)nc4C)ccc3C#N)=O)[nH]c2n1 Chemical compound CC(C)(C1=O)NCCN1c1ccc2nc(C(c(cc3-c4c(C)[n](C)nc4C)ccc3C#N)=O)[nH]c2n1 YTQVHCYNJSQYBQ-UHFFFAOYSA-N 0.000 description 1
- OOGALSDKTFQSKW-UHFFFAOYSA-N CN(C(c1ccnc(Br)c1)=O)OC Chemical compound CN(C(c1ccnc(Br)c1)=O)OC OOGALSDKTFQSKW-UHFFFAOYSA-N 0.000 description 1
- PARJWBPMHWDYPJ-UHFFFAOYSA-O CN(C)C(CC1)CCN1c(cc1)cc2c1[NH2+]CN2C Chemical compound CN(C)C(CC1)CCN1c(cc1)cc2c1[NH2+]CN2C PARJWBPMHWDYPJ-UHFFFAOYSA-O 0.000 description 1
- KGZOMQFKVAWHRO-UHFFFAOYSA-O CN(C)C(CC1)CCN1c1ccc2N=C(C(c3ccnc(Br)c3)O)[NH2+]c2c1 Chemical compound CN(C)C(CC1)CCN1c1ccc2N=C(C(c3ccnc(Br)c3)O)[NH2+]c2c1 KGZOMQFKVAWHRO-UHFFFAOYSA-O 0.000 description 1
- HYJVQCVLWVMPJG-UHFFFAOYSA-N CN(C)C(CC1)CCN1c1ccc2nc(C(c3ccnc(Br)c3)=O)[nH]c2c1 Chemical compound CN(C)C(CC1)CCN1c1ccc2nc(C(c3ccnc(Br)c3)=O)[nH]c2c1 HYJVQCVLWVMPJG-UHFFFAOYSA-N 0.000 description 1
- IWVFBEWAAWTPQT-UHFFFAOYSA-N CN(C)C(CC1)CCN1c1ccc2nc(C(c3ccnc([AlH2])c3)=O)[nH]c2c1 Chemical compound CN(C)C(CC1)CCN1c1ccc2nc(C(c3ccnc([AlH2])c3)=O)[nH]c2c1 IWVFBEWAAWTPQT-UHFFFAOYSA-N 0.000 description 1
- RFGXDIMWWFFFQX-UHFFFAOYSA-N Cc(nc1)c[n]1-c1cc(C(c2nc(ccc(N(CC3)CCC3N(C)C)c3)c3[nH]2)=O)ccn1 Chemical compound Cc(nc1)c[n]1-c1cc(C(c2nc(ccc(N(CC3)CCC3N(C)C)c3)c3[nH]2)=O)ccn1 RFGXDIMWWFFFQX-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N Cc1c[nH]cn1 Chemical compound Cc1c[nH]cn1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- IQPVSLCPAZZNAH-UHFFFAOYSA-N Cc1cnc[n]1-c1cc(C(c2nc(ccc(N(CC3)CCC3N(C)C)c3)c3[nH]2)=O)ccn1 Chemical compound Cc1cnc[n]1-c1cc(C(c2nc(ccc(N(CC3)CCC3N(C)C)c3)c3[nH]2)=O)ccn1 IQPVSLCPAZZNAH-UHFFFAOYSA-N 0.000 description 1
- JDGCZWPYIYHMFP-UHFFFAOYSA-N O=C(c1nc2ccc(CC3CCNCCC3)nc2[nH]1)c1cc(-c2cncc3c2cccc3)ncc1 Chemical compound O=C(c1nc2ccc(CC3CCNCCC3)nc2[nH]1)c1cc(-c2cncc3c2cccc3)ncc1 JDGCZWPYIYHMFP-UHFFFAOYSA-N 0.000 description 1
- RTWLIQFKXMWEJY-UHFFFAOYSA-N O=Cc1ccnc(Br)c1 Chemical compound O=Cc1ccnc(Br)c1 RTWLIQFKXMWEJY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17429309P | 2009-04-30 | 2009-04-30 | |
| US61/174,293 | 2009-04-30 | ||
| PCT/GB2010/050725 WO2010125402A1 (en) | 2009-04-30 | 2010-04-30 | Imidazole derivatives and their use as modulators of cyclin dependent kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102803225A true CN102803225A (zh) | 2012-11-28 |
Family
ID=42315726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080029384XA Pending CN102803225A (zh) | 2009-04-30 | 2010-04-30 | 咪唑衍生物和它们作为细胞周期蛋白依赖性激酶调节剂的应用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8598217B2 (enExample) |
| EP (1) | EP2424843B1 (enExample) |
| JP (1) | JP2012525367A (enExample) |
| KR (1) | KR20120004542A (enExample) |
| CN (1) | CN102803225A (enExample) |
| AU (1) | AU2010243353B2 (enExample) |
| BR (1) | BRPI1016190A2 (enExample) |
| CA (1) | CA2759083A1 (enExample) |
| EA (1) | EA020017B1 (enExample) |
| ES (1) | ES2458872T3 (enExample) |
| MX (1) | MX2011011516A (enExample) |
| PL (1) | PL2424843T3 (enExample) |
| PT (1) | PT2424843E (enExample) |
| WO (1) | WO2010125402A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218459A (zh) * | 2015-11-03 | 2016-01-06 | 广东电网有限责任公司电力科学研究院 | 苯并咪唑类金属钝化剂及其制备方法和应用 |
| CN112673000A (zh) * | 2018-09-13 | 2021-04-16 | 百时美施贵宝公司 | 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011240735B2 (en) | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| CA2826649C (en) * | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US9981918B2 (en) * | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CA2867746A1 (en) * | 2012-03-21 | 2013-09-26 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
| PE20142164A1 (es) | 2012-04-06 | 2014-12-27 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| KR20170026633A (ko) | 2014-07-17 | 2017-03-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | Hiv-관련 장애의 치료 방법 및 치료용 조성물 |
| DK3279202T3 (da) | 2015-03-31 | 2020-08-17 | Taiho Pharmaceutical Co Ltd | Krystal af 3,5-disubstitueret benzenalkynylforbindelse |
| US20180344646A1 (en) * | 2015-11-25 | 2018-12-06 | Patheon Development Services Inc. | Amorphous dispersion granules and oral dosage forms |
| KR20220110859A (ko) | 2016-03-04 | 2022-08-09 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR102700664B1 (ko) * | 2017-08-07 | 2024-08-29 | 조인트 스탁 컴퍼니 “바이오케드” | Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물 |
| MX2020009762A (es) | 2018-03-19 | 2021-01-08 | Taiho Pharmaceutical Co Ltd | Composicion farmaceutica que incluye alquil sulfato de sodio. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008044045A1 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05331163A (ja) | 1991-03-26 | 1993-12-14 | Kumiai Chem Ind Co Ltd | ピリジン誘導体及び除草剤 |
| DE4142075A1 (de) | 1991-12-19 | 1993-06-24 | Hoechst Ag | Carbocyclische fuenfringverbindungen, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika |
| JP3217848B2 (ja) | 1992-03-25 | 2001-10-15 | クミアイ化学工業株式会社 | ピリジン誘導体及び除草剤 |
| EP1052238A4 (en) | 1998-01-28 | 2007-05-02 | Shionogi & Co | NEW TRICYCLIC CONNECTION |
| CN1171872C (zh) | 1999-06-30 | 2004-10-20 | 图拉列克股份有限公司 | 调节PPARγ活性的化合物 |
| CA2381008A1 (en) | 1999-08-04 | 2001-02-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6780858B2 (en) | 2000-01-13 | 2004-08-24 | Tularik Inc. | Antibacterial agents |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| EP1363890A4 (en) | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| DE10354060A1 (de) | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | Pyrrolderivate |
| EP2284157A1 (en) | 2003-12-12 | 2011-02-16 | Wyeth | Quinolines useful in treating cardiovascular disease |
| NZ548208A (en) | 2004-02-12 | 2010-09-30 | Transtech Pharma Inc | Substituted azole derivatives, compositions, and methods of use |
| CA2637312A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| WO2008013963A2 (en) | 2006-07-28 | 2008-01-31 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
-
2010
- 2010-04-30 CN CN201080029384XA patent/CN102803225A/zh active Pending
- 2010-04-30 CA CA2759083A patent/CA2759083A1/en not_active Abandoned
- 2010-04-30 US US13/266,976 patent/US8598217B2/en not_active Expired - Fee Related
- 2010-04-30 ES ES10719772.5T patent/ES2458872T3/es active Active
- 2010-04-30 JP JP2012507826A patent/JP2012525367A/ja not_active Ceased
- 2010-04-30 WO PCT/GB2010/050725 patent/WO2010125402A1/en not_active Ceased
- 2010-04-30 EA EA201101566A patent/EA020017B1/ru not_active IP Right Cessation
- 2010-04-30 EP EP10719772.5A patent/EP2424843B1/en active Active
- 2010-04-30 KR KR1020117028530A patent/KR20120004542A/ko not_active Withdrawn
- 2010-04-30 BR BRPI1016190A patent/BRPI1016190A2/pt not_active IP Right Cessation
- 2010-04-30 PL PL10719772T patent/PL2424843T3/pl unknown
- 2010-04-30 PT PT107197725T patent/PT2424843E/pt unknown
- 2010-04-30 AU AU2010243353A patent/AU2010243353B2/en not_active Expired - Fee Related
- 2010-04-30 MX MX2011011516A patent/MX2011011516A/es active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008044045A1 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2009014637A2 (en) * | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105218459A (zh) * | 2015-11-03 | 2016-01-06 | 广东电网有限责任公司电力科学研究院 | 苯并咪唑类金属钝化剂及其制备方法和应用 |
| CN112673000A (zh) * | 2018-09-13 | 2021-04-16 | 百时美施贵宝公司 | 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺 |
| CN112673000B (zh) * | 2018-09-13 | 2024-10-18 | 百时美施贵宝公司 | 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺 |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201101566A1 (ru) | 2012-05-30 |
| MX2011011516A (es) | 2011-11-18 |
| EP2424843A1 (en) | 2012-03-07 |
| AU2010243353A1 (en) | 2011-11-10 |
| US20120101064A1 (en) | 2012-04-26 |
| US8598217B2 (en) | 2013-12-03 |
| WO2010125402A1 (en) | 2010-11-04 |
| KR20120004542A (ko) | 2012-01-12 |
| CA2759083A1 (en) | 2010-11-04 |
| AU2010243353B2 (en) | 2014-09-11 |
| PL2424843T3 (pl) | 2014-07-31 |
| PT2424843E (pt) | 2014-06-02 |
| JP2012525367A (ja) | 2012-10-22 |
| BRPI1016190A2 (pt) | 2017-03-28 |
| ES2458872T3 (es) | 2014-05-07 |
| EA020017B1 (ru) | 2014-08-29 |
| EP2424843B1 (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102803225A (zh) | 咪唑衍生物和它们作为细胞周期蛋白依赖性激酶调节剂的应用 | |
| JP6959299B2 (ja) | 新規化合物 | |
| RU2682245C1 (ru) | Индазольные ингибиторы сигнального пути wnt и их терапевтические применения | |
| JP6355648B2 (ja) | Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用 | |
| ES2989326T3 (es) | Compuestos de benzolactama como inhibidores de la proteína cinasa | |
| US10206909B2 (en) | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | |
| JP7023243B2 (ja) | イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法 | |
| US10350199B2 (en) | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | |
| US10604512B2 (en) | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof | |
| US9738638B2 (en) | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | |
| US10604514B2 (en) | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof | |
| BR112014024284B1 (pt) | Compostos de 1h-pirazolo[3,4-b]piridinas, composição farmacêutica compreendendo ditos compostos e usos terapêuticos destes | |
| CN109195972A (zh) | 作为ret激酶抑制剂的杂环化合物 | |
| US20240148733A1 (en) | Combination therapy | |
| JP2008505167A (ja) | 医薬組成物 | |
| KR20190034620A (ko) | 피페리딘 cxcr7 수용체 조절제 | |
| KR20150126687A (ko) | 피리디닐 및 융합 피리디닐 트리아졸론 유도체 | |
| JP6190076B2 (ja) | 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用 | |
| JP4895220B2 (ja) | キネシン有糸分裂インヒビター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Applicant after: Astex Therapeutics Ltd. Address before: Basel Applicant before: Novartis AG Applicant before: Astex Therapeutics Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121128 |